Abstract. Using an existing ordinary differential equation model which describes the interaction of the immune system with the human immunodeficiency virus (HIV), we introduce chemotherapy in an early treatment setting through a dynamic treatment and then solve for an optimal chemotherapy strategy. The control represents the percentage of effect the chemotherapy has on the viral production. Using an objective function based on a combination of maximizing benefit based on T cell counts and minimizing the systemic cost of chemotherapy (based on high drug dose/strength), we solve for the optimal control in the optimality system composed of four ordinary differential equations and four adjoint ordinary differential equations.
Introduction
Of great concern today is the treatment of patients infected with the human immunodeficiency virus (HIV). Different chemotherapies are continually being tested and, even once FDA approved, these are under intense study to find the optimal methodology for administering the treatment.
Presently, the most widely used drugs for chemotherapy of HIV infection are AZT, DDI, DDC and D4T. These drugs all work as inhibitors of reverse transcriptase which is an enzyme. HIV is an RNA virus. When HIV infects a human immune cell (the ones we are concerned with here are the CD4> T cells), its RNA is transcribed into DNA (a unique feature of a retrovirus) using the enzyme reverse transcriptase. Reverse transcriptase inhibitors interfere with this process by halting the cellular infection and the growth of virus.
There are many data available on the treatment of HIV infection (cf., [25, 18] ) and many laboratories and clinics are keeping close accounts of patient treatment courses with respect to effectiveness and results. Of interest here is the fact that there are conflicting results as to whether treatment is better at the early stage of disease (when the CD4> T cell count is between 200/mm and 500/mm of blood), (see [13, 15] ) or at the later stage (when the count is below 200/mm) [16, 11] . The recent Concorde study was devoted entirely to this issue [8] .
There are a few models which study the effects of chemotherapy on an immune system infected with HIV. For example, McLean and Nowak [26] have presented a model which addresses the complications arising from the appearance of AZT-resistant strains of HIV during treatment. Agur [2] and Cojocaru and Agur [7] have examined the effects of chemotherapy on normal, uninfected cells through cell cycle drug protocols. Kirschner and Webb [21] developed a model which incorporates the application of chemotherapy in the periodic manner in which it is presently administered, thus affecting only those cells which are in the early stages of infection. This is done by marking the age of cellular infection.
Kirschner and Perelson, [20] , introduce to their model the effect of a drug that reduces viral replication by multiplying the terms responsible for viral load by a scalar step function,
z(t)"
1 outside the treatment period P during the time of AZT treatment .
Since most chemotherapies reduce viral production in a dose-dependent manner, P is chosen to be proportional to the dose of the drug. (Another interpretation for the proportion P is that efficacy of the drug may differ from patient to patient; therefore, P could also represent the varying effectiveness of the drug in halting viral reproduction.) The results in [20] indicate that introducing treatment at the beginning of the T cell depletion, when T cell counts are still relatively high, seems to be the most beneficial in restoring and mantaining T cell counts. When given in the early stages of the disease, the drug increases the time to profound T cell depletion, which suggests an increase in the time to the onset of opportunistic infections.
A problem arising from the use of most chemotherapies is the multiple and sometimes harmful side effects, as well as the ineffectiveness of treatment after a certain time due to the capability of the virus to mutate and become resistant to the treatment. Although we do not intend to model effects of resistance or side effects, we impose a condition called a limited treatment window, that monitors the global effects of these phenomena: The treatment lasts for a given period from time tstart to tfinal, say. The results, however, are not intervaldependent.
This paper deals specifically with the question of optimizing treatment scheduling; i.e., when and how treatment should be initiated. This study focuses on patients who are in the early stages of infection where T cell counts are high. Health and civil workers, for example, know the moment of infection and may want to treat under asymptomatic conditions. We base the 'benefit' of treatment solely on an increase or retention of the CD4> T cell count. To this end, in Sect. 2, we introduce an existing model that describes the interaction of HIV with the immune system. Section 3 presents the optimal control problem in which the coefficient of the viral production term is the control, resulting from chemotherapy. We seek to maximize the objective function, which is the benefit based on T cell counts less the systemic cost of chemotherapy. The optimal control is characterized by use of Pontryagin's Maximum Principle. In Sect. 4, utilizing the representation of the optimal control, we solve numerically the optimality system, which is defined as the original state system coupled with the adjoint system. We conclude by discussing the results of the numerical simulations as treatment initiation is varied.
Presentation of a working model
To begin the control procedure, it is necessary to have a model which describes the infected scenario. In [29, 30] , a simple model is given which simulates the interaction of the immune system with HIV. We use this model and recommend that the reader see those papers for a more complete background and analysis of the model. We present a brief discussion below.
Let ¹ denote the concentration of uninfected CD4> T cells, and let ¹ * and ¹ ** denote the concentrations of latently infected and actively infected CD4> T cells. The concentration of free infectious virus particles is ». Definitions and numerical information for the parameters can be found in Table 1 . We assume that the dynamics of the various populations are:
In (1), s/(1#» ) is a source term and represents the rate of generation of new CD4> T cells. T cells have a finite life-span and die at a rate of 2 per cell. In (2), latently infected T cells are also assumed to have the same natural death-rate, 2
, although other factors can augment the natural death rate.
We obtained the best results as compared to the clinical data (e.g., [9] ), when we allowed the source of CD4> T cells to be a monotonically decreasing function depending on the viral concentration, ». This viral dependent source models the infection of T cell precursors by virus, hence which reduces the uninfected viral source. This is explored more fully in [22] . That is, we assume that although the cell is a host to virion, it is unaffected by their presence. In (1), r represents the growth rate of T cells, which is presented as a logistic-type term, so that the T cells never grow larger than a value, ¹ . The other terms in (1) and (2) deal with the effects of HIV. The term k »¹ models the rate at which free virus » infects CD4> T cells. Once a ¹ cell has been infected, it becomes a latently infected or ¹ * cell, so k »¹ thus this term is subtracted from (1) and added to (2) .
Equation (3) models the actively infected CD4> T population. Latently infected cells become actively infected at the rate k ¹ *. Actively infected cells produce virus and die at per capita rate @ . Equation (4) models the free virus population. We assume that when an actively infected CD4> T cell becomes stimulated through exposure to antigen, replication of the virus is initiated and N viruses are produced before the host cell dies. Free virus is lost by binding to uninfected CD4> T cells at rate k »¹. Infected cells tend to lose their CD4, and hence their binding to infected cells is ignored. The next term, ! 4 », accounts for viral loss of infectivity and/or removal from the body. In the absence of virus, the T cell population has the steady state value
Thus reasonable initial conditions for the system of equations (1)- (4) are
infection by both infected cells and virus.
There are certain parameter restrictions that we impose to ensure that this model gives realistic population dynamics. See [30] for the analysis leading to parameter restrictions and stability results. Even after the thymus involutes (a normal process is adulthood by where the thymus retrogresses), the thymus still remains functional. Thus, we assume s'0. The steady state population size, ¹ should be less than ¹ , so that the T cell population will expand when stimulated as occurs during infection with HIV. Further, after the population reaches ¹ , it should decrease. Therefore, for the death rate at ¹ to be greater than the supply rate, we choose
If this were not the case, then the population could increase past ¹ . Equations (5) and (6), together with the condition s'0, imply that ¹(t)(¹ as desired. Thus, all solutions that begin with an initial number of T cells, ¹(0) in the interval (0, ¹ ) remain bounded and in that corresponding interval for all t.
The system (1)- (4) has two steady states. The first, when no virus is present (the uninfected steady state), occurs when ¹"¹ , ¹ *"0, ¹ **"0 and »"0. The second, the endemically infected steady state, has each of the cell populations at positive values. Perelson et al. [30] showed that if the parameter N was below a critical value, N , the uninfected steady state is stable and the infected steady state is unstable. At N"N , the stability is exchanged through a transcritical bifurcation and the infected steady state becomes locally stable. For N'N , global stability could not be shown because other bifurcations may occur. For example, stability can be lost for the infected steady state, giving rise to stable limit cycles. Perelson et al. [30] believe that this occurs for parameter values that lie outside of the biologically possible ranges.
In Perelson et al. [30] and Kirschner and Perelson [20] chemotherapy was studied with this simple model and a related one. Treatment was simulated by a drug which reduces viral production. The models showed that if the number of virion product per CD4> T cell is forced below N through treatment, then the immune system can recover to state where the uninfected state is stable. Otherwise, infection continues.
Optimally controlling chemotherapy
Our control represents the percentage of effect the chemotherapy has on the viral production. As in the previous work done with chemotherapy and HIV ( [30, 20] ), we assume that the chemotherapy reduces the viral load, so in equations (1)- (4), the control u(t) multiplies the parameter N in equation (4) . Therefore, we choose as our control class, measurable functions defined on [tstart, tfinal] , with the restriction 06u(t)61. Although we do not intend to model effects of resistance or side effects, we can impose a condition that monitors the global effects of these phenomena: a limited treatment window. Thus, a finite interval of treatment is necessary since we assume HIV has the ability to mutate at such a fast pace that it is able to build up resistance to the chemotherapy treatment after a finite time. The treatment period is finite in any treatment scenario. Also, the treatment has potentially harmful side effects. Therefore, for tstart6t6tfinal where, for most of the present HIV chemotherapy drugs, tfinal!tstart(2 years, the state system would be:
with given initial values for ¹, ¹ *, ¹ **, and » at tstart. For our purposes, we use N'N so we are not in the region of stability for the uninfected state.
Define the objective function
In words, we are maximizing the benefit based on the T cell count, and minimizing the systemic cost based on the percentage effect of the chemotherapy given (i.e. (1!u)), since large drug concentrations can be harmful; hence, we are maximizing the difference. We have reason to believe that the cost function is a nonlinear function of u*; we choose a quadratic cost here. This is based on the fact that there is not a linear relationship between the effects of treatment on T cells or virus. If the control u(t)"0 corresponds to maximal use of chemotherapy, then the maximal cost is represented as (1!u(t)). The parameter B70 represents the desired 'weight' on the benefit and cost. The goal, therefore is to characterize the optimal control u* satisfying, max
J(u)"J(u*).
We note that the existence of an optimal control can be found in Fleming and Rishel ( [14] , chapter III). In this maximization problem, the necessary concavity of the objective functional in u holds. The right hand sides of the state equations are linearly bounded, due to a priori bounds on the ¹ variable, which implies the needed a priori bounds on the other state variables. These bounds insure the compactness needed for the existence of the optimal control. At this point we can proceed with the Pontryagin Maximum Principle.
If u* is an optimal control, then we apply Pontryagin's Maximum Principle to the constrained control problem [19] . The Lagrangian for our problem is the integrand of the objective functional, coupled with the right hand sides of the state equations through the adjoint variables (t), (t), (t). Penalty multipliers (t), (t) attach the control con-straints. Define the Lagrangian to be: (12) where (t)70, (t)70, are the penalty multipliers satisfying (t)u(t)"0, and (t)(1!u(t))"0. Thus, the Maximum Principle gives the existence of adjoint variables satisfying: "
where G (tfinal)"0 for i"1, 2, 3, 4 are the transversality conditions. The Lagrangian is maximized with respect to u at the optimal u*, so the derivative of the Lagrangian with respect to u at u* is zero. Sincȩ
differentiating this expression for¸with respect to u gives:
Solving for the optimal control yields
Consider 3 cases: (i) For +t " 0(u*(t)(1,, we have (t)" (t)"0, hence the optimal control is:
(ii) For +t " u*(t)"1,, we have (t)"0 hence, u*(t)"1" N @ ¹ **! (t)/B#1, which implies 06 (t)" N @ ¹ **, and 16( N @ ¹ **#B)/B; (iii) For +t " u*(t)"0,, we have (t)"0, (t)70. Hence, the optimal control is:
Therefore, (t)70 implies that (
Combining these 3 cases, the optimal control is characterized as
where
. If (t)(0 for some t, then u*(t)91. Hence, 06u*(t)(1 for those t, which implies treatment should be administered.
Theorem An optimal control u* for system (7)-(10) which maximizes the objective function (11) is characterized by (17) , where the notation a>"max +a, 0,.
The uniqueness of solutions to the optimality system, (7)-(10) coupled with (13)- (16) together with u* characterization (17), can be obtained by standard results. Thus the unique optimal control is represented in terms of the unique solution of the optimality system. Note that we could have easily treated the case 6u61, '0, which would say that the chemotherapy never completely stopped viral reproduction.
Numerical results
The numerical results of the untreated model (1)-(4) were created using Mathematica [33] , and are presented in Fig. 1 . We present these results for comparison purposes. Numerical results for the optimality system of eight Table 1 equations are also presented. We point out that for the state variables, ¹, ¹ *, ¹ **, », we have given a priori initial conditions. However, for the adjoint variables, G , i"1, 2, 3, 4, we have only the ending values G (t DGL?J )"0, i"1, 2, 3, 4. The problem is thus a two-point boundary value problem. Using a collocation code COLNEW [1, 4] (obtained via NETLIB), the optimality system was solved. Figures 2-4 represent the graphs of the solution to the optimality system (7-10) coupled with (12) (13) (14) (15) (16) at three different early treatment initiations. We vary initiation of treatment beginning with T cell counts: at 950/mm, 800 days after the onset of infection (Fig. 2) ; at 890/mm, 1000 days after the onset of infection (Fig. 3) ; at 760/mm, 1200 days after onset of infection (Fig. 4) . We ran simulations with different values of B, the control parameter which adjusts the balance between benefit of treatment and systemic cost of chemotherapy, but present only the case B"100 for brevity. This is because the magnitude of T cell concentration is much larger than the magnitude of the chemotherapy cost in the objective function in (11) . Therefore, this difference in magnitudes is best balanced by choosing B on the order of a hundred to represent this magnitude difference. We also examined different treatment periods (in number of days) but found that there was not much variation in the results so we only show the case of 500 days of treatment. Fig. 2a-d . Graph of the solution to the optimality system (7-10) coupled with (12) (13) (14) (15) (16) . The control, u* is defined in (17) . Here we initiate treatment after 800 days (T cell count is 975) for a treatment period of 500 days. Fig. 3a-d . Graph of the solution to the optimality system (7-10) coupled with (12) (13) (14) (15) (16) . The control, u* is defined in (17) . Here we initiate treatment after 1000 days (T cell count is 900) for a treatment period of 500 days. Table 2 is a summary of these results. These simulations reveal that earliest treatment, with a moderate treatment schedule, is optimal. Notice that, in the last panel with treatment initiated at 760 T cells/mm, the treatment must be given at the highest possible dose for almost 100 days to achieve basically the same effect at the first case, where treatment is never administered at 100% strength.
Conclusions
We have used an optimal control theory paradigm to model HIV chemotherapy. Our approach uses an existing model for the interaction of HIV with the immune system and then includes a chemotherapy control as a way to suppress viral production, N. We use methods of optimal control to determine the optimal dynamic control analytically, then use numerical methods to simulate different outcomes.
Numerical results indicate that the optimal chemotherapy is a dynamic one, in which treatment is adjusted over the long course of administration whereby one begins with a strong dosing scheme, followed by a lessening of treatment (either by drug dosing or strength).
We can also draw from the control problem that the dynamic optimal chemotherapy does not correspond to a regime where treatment is 100% effective, 100% of the time. Rather, if treatment is strong at the outset, and then gradually lessens in strength over time (whether because of a change in dosage or other effects), it is still effective in balancing the benefit to T cells and systemic costs. This is seen, in particular, with drug treatments such as with AZT and DDT [25] .
Exploring initiation of treatment, Table 2 compares the values of the objective function, J at the optimal control u*. There is not a significant difference between the three presented scenarios; however the greatest effect of treatment does occur when treatment is initiated earliest -i.e. when T cell counts are highest, after the onset of infection. The recovery of T cells to larger values makes the biggest difference late in infection after the T cells have begun to decline significantly; but balanced with the effects of drug cost, the earlier-initiated treatment is optimal.
The results presented here do not depend on the treatment duration. When one is comparing different treatment intervals, the results are the same: namely, that the earlier treatment is better no matter what the length of the treatment interval.
The model studied here is a simple one, and further studies need to be done to incorporate a more accurate model of the immune system and such things as direct pharmacology for combined drug treatments together with the resistance effects. This model and the analysis presented here provides a simple framework for the testing and development of such models, which can lead to new and improved chemotherapy strategies.
Finally, it is worrisome that early treatment of HIV infection with drug chemotherapy may, and usually has, led to drug resistance. This, of course, will reduce the time period over which therapy can be administered. New research suggests that combination drug treatments is preferable since there is a reduced chance of the virus mutating simultaneously to strains resistant to all of the drugs present in the 'cocktail' [6, 27] . We are presently exploring these phenomena through a revised model.
